Internal Server Error

PerMED AI - About the company

PerMED AI is an unfunded company. It operates as a Developer of transcriptome analysis tools ranking cancer therapies by pathway. PerMED AI has not raised any funding yet. The company has 467 active competitors, including 128 funded and 100 that have exited. Its top competitors include companies like Guardant Health, Natera and BillionToOne.

Company Details

Developer of transcriptome analysis tools ranking cancer therapies by pathway. This process utilizes paired RNA and DNA sequencing from tumor specimens to measure pathway activation levels. The platform identifies active drivers that standard mutation panels may overlook by normalizing gene expression against reference tissue. Results provide a ranked list of systemic agents based on the underlying biological signals found within the tumor transcriptome. This analysis serves as clinical decision support for molecular tumor boards, providing evidence on contributing genes and signaling interactions to assist in therapy selection. The workflow integrates genomic and transcriptomic data from a single specimen to determine target pathway activity.
Key Metrics
Stage
Unfunded
Ranked
502nd among 597 competitors
Similar Companies
Sign up to download PerMED AI's company profile

PerMED AI's funding and investors

PerMED AI has not raised any funding rounds yet.

chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

PerMED AI's Competitors and alternates

Top competitors of PerMED AI include Guardant Health, Natera and BillionToOne. Here is the list of Top 10 competitors of PerMED AI, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for Guardant Health
Guardant Health
2012, Redwood City (United States), Public
Developer of digital sequencing technology for cancer detection
$557M
80/100
2nd
Logo for Natera
Natera
2004, Redwood City (United States), Public
Developer of cell-free DNA testing for oncology, women’s health, and organ health
$152M
79/100
3rd
Logo for BillionToOne
BillionToOne
2015, San Francisco (United States), Public
Provider of cell-free cancer liquid biopsy test
$389M
71/100
4th
Logo for Caris Life Sciences
Caris Life Sciences
1996, Irving (United States), Public
Developer of panomic disease profiling technologies for cancer precision medicine
$1.23B
67/100
5th
Logo for Foundation Medicine
Foundation Medicine
2010, Cambridge (United States), Acquired
Provider of genomics-based diagnostics test for cancer
$96.5M
66/100
6th
Developer of molecular diagnostics and personalized medicine for cancer
-
66/100
7th
Logo for Prenetics
Prenetics
2009, Hong Kong (China), Public
Online platform for genetic and diagnostic health testing that helps identify health risks
$67.6M
65/100
8th
Logo for NeoGenomics
NeoGenomics
2002, Fort Myers (United States), Public
Provider of cancer genetic diagnostic services
-
65/100
9th
Logo for Saga Diagnostics
Saga Diagnostics
2016, Morrisville (United States), Acquired
Provider of tests for detection and analysis of circulating tumor DNA
$17.9M
65/100
10th
Logo for Foresight Diagnostics
Foresight Diagnostics
2020, Aurora (United States), Acquired
Developer of minimally-invasive liquid biopsy test for the detection of cancer
$104M
62/100
502nd
Logo for PerMED AI
PerMED AI
Unfunded
Developer of transcriptome analysis tools ranking cancer therapies by pathway
-
-
16/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on PerMED AI's competitors? Click here to see the top ones

PerMED AI's Investments and acquisitions

PerMED AI has made no investments or acquisitions yet.

Reports related to PerMED AI

Here is the latest report on PerMED AI's sector:

FAQs about PerMED AI

Explore our recently published companies
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford